# Dose Escalation Study of JNJ-63709178, a Humanized CD123 x CD3 DuoBody in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)

> **NCT02715011** · PHASE1 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 62 (actual)

## Conditions studied

- Leukemia, Myeloid, Acute

## Interventions

- **DRUG:** JNJ-63709178

## Key facts

- **NCT ID:** NCT02715011
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06-01
- **Primary completion:** 2021-03-26
- **Final completion:** 2021-03-26
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2021-08-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02715011

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02715011, "Dose Escalation Study of JNJ-63709178, a Humanized CD123 x CD3 DuoBody in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02715011. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*